Welcome to our dedicated page for Pulmatrix SEC filings (Ticker: PULM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulmatrix, Inc. (PULM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on Nasdaq. These filings document material events, financial performance and key developments affecting Pulmatrix’s inhaled therapeutic pipeline and strategic transactions.
Investors can review Pulmatrix’s Current Reports on Form 8-K, which the company uses to report significant events such as quarterly financial results, corporate updates and merger-related developments. For example, Pulmatrix has filed 8-Ks furnishing press releases on its first, second and third quarter 2025 financial results and corporate updates, as well as an 8-K describing a mutual waiver agreement related to its merger agreement with Cullgen Inc. These filings incorporate press releases that discuss Pulmatrix’s iSPERSE™-based programs, cost-saving measures and anticipated cash runway.
Filings associated with the proposed merger with Cullgen are particularly relevant. Pulmatrix references a registration statement on Form S-4, which was declared effective by the SEC, and stockholder approval of the merger and related proposals. While the Form S-4 itself is filed separately, related 8-Ks and other Exchange Act reports provide context on the transaction structure, closing conditions and subsequent waiver arrangements between Pulmatrix and Cullgen.
Through this page, users can also monitor Pulmatrix’s periodic reports, such as Forms 10-K and 10-Q (when available in the feed), which typically contain detailed discussions of its clinical programs, iSPERSE™ patent portfolio, collaborations with partners like Cipla and MannKind Corporation, and risk factors. Form 4 and other insider transaction filings, when present, can help readers understand equity activity by directors and officers.
Stock Titan enhances these SEC documents with AI-powered summaries that explain the key points of lengthy filings in plain language. Real-time updates from EDGAR ensure that new Pulmatrix filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports and Form 4 insider trading disclosures, are quickly reflected. This allows investors and researchers to navigate Pulmatrix’s regulatory history and understand how clinical, financial and strategic developments are formally reported to the SEC.
Pulmatrix (PULM) Q2-25 10-Q highlights: revenue fell to $0 from $1.6 m YoY as development work on PUR1900 wound down. Operating expenses dropped sharply to $1.5 m (-79%), driven by a 98% reduction in R&D to $14 k after the MannKind facility divestiture and staff cuts. Net loss narrowed to $1.5 m (-73%), or -$0.42/sh versus -$1.59/sh last year. Six-month net loss improved to $3.4 m from $5.0 m.
Cash & equivalents declined to $5.8 m (Dec-24: $9.5 m) after $3.7 m operating cash burn; management believes liquidity covers ≥12 months if the Cullgen merger is not completed. Stockholders’ equity fell to $5.6 m.
Cullgen merger: approved by Pulmatrix holders on 16-Jun-25; closing now targeted by 12-Oct-25 pending CSRC and Nasdaq approvals. Pre-merger Pulmatrix investors will receive a cash dividend for net cash above $2.5 m and retain only ~3.6% pro-forma ownership. Termination fees range from $0.42 m to $8.4 m. Failure to close could push Pulmatrix toward liquidation or require new funding.
Warrant liability was re-measured to $0, creating a $67 k gain; 918 k warrants remain outstanding, many expiring July-25. No ATM sales occurred in H1-25; share count steady at 3.65 m.